The withdrawal is a big blow for Merck, which is already reeling from the failure of two of its most important new medicines in clinical trials.

• 撤回罗非考昔对默克是一个沉重打击。此前,该公司两种最重要的新药在临床试验中失败,已令公司受到很大打击。